Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Funding Opportunities / Notice of Availability of Administrative Supplements for Discovery of Cancer Biomarkers in the HIV/AIDS Population

Notice of Availability of Administrative Supplements for Discovery of Cancer Biomarkers in the HIV/AIDS Population


Key Dates
Release Date: June 6, 2008
Receipt Date: July 10, 2008

Issued by
National Cancer Institute (NCI), (


The Division of Cancer Prevention, NCI, has set apart funds in fiscal year 2008 (FY08) that are specifically designated for studies on biomarkers of AIDS and HIV-associated cancers. The NCI is requesting applications for administrative supplements for NCI-funded U01 or U24 awards associated with the Early Detection Research Network or the Alliance of Glycobiologists for Detection of Cancer or Cancer Risk.

The NCI has particular interest in investigators who might seek to complement their research on cancer biomarkers with studies on HIV-positive individuals who develop cancer. Effective therapies to treat AIDS have led to prolonged survival of HIV-infected patients. While antiretroviral therapy has diminished risk to the development of cancers such as Kaposi’s sarcoma and non-Hodgkin’s lymphoma, the likelihood of developing these cancers still remains higher in this population than in the non-infected population. Moreover, preliminary data suggests that this population is now exhibiting a significant risk of developing certain non-AIDS defining malignancies such as anal, colorectal, lung, oropharyngeal, liver, renal, and vaginal cancers as well as melanoma and Hodgkin’s lymphoma. The NCI is interested in supporting studies to identify biomarkers for these AIDS-related malignancies and determine if the biomarker profiles differ from those in the noninfected population.

Several repositories are available for appropriate studies on AIDS-related malignancies. The NCI Office of the AIDS Malignancy Program supports the AIDS and Cancer Specimen Resource ( which provides AIDS malignancy biospecimens to qualified investigators. Other repositories are supported by NIH programs such as the Multicenter AIDS Cohort Study ( and Women’s Interagency HIV Study ( These programs have developed extensive repositories of prospectively and longitudinally collected patient samples. The AIDS Malignancy Program will assist interested qualified investigators in providing access to these repositories of collected specimens from HIV-positive subjects.

Projects related to malignancies occurring with higher prevalence in the HIV-infected population are particularly encouraged. Projects may also focus on malignancies showing equal prevalence between infected and non-infected populations in relation to comparisons of biomarker signatures between both populations. Examples of research objectives for the supplements may include:  1) Discovery of new biomarkers relevant to cancers that have been shown to occur at an increased rate in the HIV-infected population,e.g., anal cancer, Hodgkin lymphoma, liver cancer and lung cancer. 2) Determination of whether biomarkers associated with cancers of the HIV-infected population have similar specificity and sensitivity in histologically identical cancers in the non-infected population. 3) Study strategic screening processes to define risks for developing cancers in the HIV-infected population. 4) Develop biomarkers for viral associated cancers that often occur in HIV-infected populations. 5) Studies identifying biomarkers that may be used to assess progression or treatment outcome of HIV-associated malignancies.

Detailed instructions for applying for these administrative supplements are posted at . The receipt date for administrative supplement applications is July 10, 2008. Before submitting a proposal, each applicant (i.e., PI) is encouraged to discuss the feasibility of their research proposal with one of the Program Directors listed below.

The earliest anticipated award date for this program will be September 1, 2008. A final report is due at the conclusion of this supplemental funding.


Inquiries concerning scientific, programmatic and review matters should be directed to:

Karl Krueger, Ph.D.
Program Director
Cancer Biomarkers Research Group
Division of Cancer Prevention
6130 Executive Boulevard, MSC 7368
Bethesda, MD 20892-7368 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 594-1044
Fax:  (301) 402-8990

For specific inquiries concerning AIDS-associated malignancies please contact:

Geraldina Dominguez, Ph.D.
Program Director
Office of HIV and AIDS Malignancy
National Cancer Institute
6120 Executive Blvd, MSC 7204
Bethesda, MD 20892-7204
Voice: 301-496-3204
Fax:    301-480-4137

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.